Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

Filippatos TD, Elisaf MS.

J Thorac Dis. 2017 Aug;9(8):2308-2310. doi: 10.21037/jtd.2017.07.75. No abstract available.

2.

How radiation influences atherosclerotic plaque development: a biophysical approach in ApoE[Formula: see text] mice.

Kloosterman A, Dillen TV, Bijwaard H, Heeneman S, Hoving S, Stewart FA, Dekkers F.

Radiat Environ Biophys. 2017 Nov;56(4):423-431. doi: 10.1007/s00411-017-0709-2. Epub 2017 Sep 2.

3.

Local Vascular Gene Therapy With Apolipoprotein A-I to Promote Regression of Atherosclerosis.

Wacker BK, Dronadula N, Zhang J, Dichek DA.

Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):316-327. doi: 10.1161/ATVBAHA.116.308258. Epub 2016 Dec 8.

PMID:
27932352
4.

Targeted Nanotherapies for the Treatment of Surgical Diseases.

Morgan CE, Wasserman MA, Kibbe MR.

Ann Surg. 2016 May;263(5):900-7. doi: 10.1097/SLA.0000000000001605. Review.

5.

SR-BI/CD36 chimeric receptors define extracellular subdomains of SR-BI critical for cholesterol transport.

Kartz GA, Holme RL, Nicholson K, Sahoo D.

Biochemistry. 2014 Oct 7;53(39):6173-82. doi: 10.1021/bi500706x. Epub 2014 Sep 23.

6.

Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: cardiovascular Health Study.

Tehrani DM, Gardin JM, Yanez D, Hirsch CH, Lloyd-Jones DM, Stein PK, Wong ND.

Atherosclerosis. 2013 Dec;231(2):246-51. doi: 10.1016/j.atherosclerosis.2013.08.036. Epub 2013 Sep 5.

7.

Plasma apolipoprotein A1 as a biomarker for Parkinson disease.

Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM, Trojanowski JQ, Yearout D, B Leverenz J, Montine TJ, Stern M, Mendick S, Jennings D, Zabetian C, Marek K, Chen-Plotkin AS.

Ann Neurol. 2013 Jul;74(1):119-27. doi: 10.1002/ana.23872. Epub 2013 Aug 6.

8.

Functional genomics of the human high-density lipoprotein receptor scavenger receptor BI: an old dog with new tricks.

Chadwick AC, Sahoo D.

Curr Opin Endocrinol Diabetes Obes. 2013 Apr;20(2):124-31. doi: 10.1097/MED.0b013e32835ed575. Review.

9.

High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity.

Chantepie S, Bochem AE, Chapman MJ, Hovingh GK, Kontush A.

PLoS One. 2012;7(11):e49336. doi: 10.1371/journal.pone.0049336. Epub 2012 Nov 26.

10.

Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.

Goldberg AS, Hegele RA.

Drug Des Devel Ther. 2012;6:251-9. doi: 10.2147/DDDT.S34976. Epub 2012 Sep 24. Review.

11.

Functional characterization of newly-discovered mutations in human SR-BI.

Chadwick AC, Sahoo D.

PLoS One. 2012;7(9):e45660. doi: 10.1371/journal.pone.0045660. Epub 2012 Sep 21.

12.

Crystal structures of cholesteryl ester transfer protein in complex with inhibitors.

Liu S, Mistry A, Reynolds JM, Lloyd DB, Griffor MC, Perry DA, Ruggeri RB, Clark RW, Qiu X.

J Biol Chem. 2012 Oct 26;287(44):37321-9. doi: 10.1074/jbc.M112.380063. Epub 2012 Sep 7.

13.

High Density Lipoprotein and it's Dysfunction.

Eren E, Yilmaz N, Aydin O.

Open Biochem J. 2012;6:78-93. doi: 10.2174/1874091X01206010078. Epub 2012 Jul 27.

14.

Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Mahdy Ali K, Wonnerth A, Huber K, Wojta J.

Br J Pharmacol. 2012 Nov;167(6):1177-94. doi: 10.1111/j.1476-5381.2012.02081.x. Review.

15.

Role of apolipoprotein A-II in the structure and remodeling of human high-density lipoprotein (HDL): protein conformational ensemble on HDL.

Gao X, Yuan S, Jayaraman S, Gursky O.

Biochemistry. 2012 Jun 12;51(23):4633-41. doi: 10.1021/bi300555d. Epub 2012 Jun 1.

16.

The Association between Apolipoprotein A-II and Metabolic Syndrome in Korean Adults: A Comparison Study of Apolipoprotein A-I and Apolipoprotein B.

Yi DW, Jeong DW, Lee SY, Son SM, Kang YH.

Diabetes Metab J. 2012 Feb;36(1):56-63. doi: 10.4093/dmj.2012.36.1.56. Epub 2012 Feb 17.

17.

Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease.

Martinelli N, Micaglio R, Consoli L, Guarini P, Grison E, Pizzolo F, Friso S, Trabetti E, Pignatti PF, Corrocher R, Olivieri O, Girelli D.

Exp Diabetes Res. 2012;2012:231502. doi: 10.1155/2012/231502. Epub 2011 Sep 22.

18.

Association between moderately oxidized low-density lipoprotein and high-density lipoprotein particle subclass distribution in hemodialyzed and post-renal transplant patients.

Kimak E, Hałabiś M, Baranowicz-Gąszczyk I, Solski J, Książek A.

J Zhejiang Univ Sci B. 2011 May;12(5):365-71. doi: 10.1631/jzus.B1000348.

19.

Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.

Lukasova M, Malaval C, Gille A, Kero J, Offermanns S.

J Clin Invest. 2011 Mar;121(3):1163-73. doi: 10.1172/JCI41651. Epub 2011 Feb 7.

20.

High density lipoproteins-based therapies for cardiovascular disease.

Gao X, Yuan S.

J Cardiovasc Dis Res. 2010 Jul;1(3):99-103. doi: 10.4103/0975-3583.70898.

Supplemental Content

Support Center